Abstract 45P
Background
Immune related adverse events (IrAEs) are a growing challenge in oncology affecting an increasing number of patients and putting a large strain on patient health and hospital resources. The current availability of biomarkers is highly dependent on the affected organ and the management strategy based on consensus or experiences with non-CPI induced autoimmune disease. In this study, we apply proteome analysis of extracellular vesicles from plasma to assess and discover biomarkers with the potential to aid clinical staging and care of patients suffering from IrAEs.
Methods
Thirty-six patients with grade 3-4 IrAEs (colitis, hepatitis or nephritis) were included in the study. Blood samples were collected at hospital admittance before or early in management (At tox), after initiation of high dose immunosuppressive therapy (At management) and after management (After tox). The collected plasma samples were enriched for extracellular vesicles using a novel workflow and analyzed using liquid-chromatography tandem mass spectrometry (LC-MS/MS). The data analysis was performed in R using the Limma package.
Results
The sample workflow allowed median quantification of 2015 proteins in the plasma samples. In patients responding to prednisolone, we found significant decreases in CRP, SAA1 and SAA2 and a significant increase in MMP9 At management compared to At tox. CRP, SAA1 and SAA2 together with EPS8 and CFP was also significantly lowered After tox. By comparing the IrAE subtypes, definite proteins associated to specific toxicities could be identified including ALDOB, ASL and DXCR in hepatitis, SLC47A2 and PRPF40A in colitis and NCAPH in nephritis.
Conclusions
Biomarkers for monitoring IrAE management are needed to improve the clinical care of patients. Our study identifies several proteins that correlate to specific types of IrAEs and to response to toxicity management, thus, constituting relevant IrAE biomarker candidates.
Clinical trial identification
Regional Ethical Commitee reference number: H-21027448.
Legal entity responsible for the study
Capital Region of Denmark.
Funding
Novo Nordisk Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
181P - Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
Presenter: Jitka Palich Fucikova
Session: Poster Display
182P - Exploring Cross-Compartmental Tumor Cell Plasticity and Immunogenicity in Serous Ovarian Cancer
Presenter: Louisa Hell
Session: Poster Display
183P - Multi-omics Investigation Reveals Cancer-Associated Fibroblast-Secreted FGF7 as an Ovarian Cancer Progression Promoter through HIF-1_/EMT Modulation
Presenter: Songwei Feng
Session: Poster Display
184P - Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study.
Presenter: LUCIA CARRIL AJURIA
Session: Poster Display
185P - The Immunosuppressive Landscape of Leukemia Inhibitory Factor (LIF) in Clear Cell Renal Cell Carcinoma
Presenter: Yazan Al Zu’bi
Session: Poster Display
186P - Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: an EORTC IMMUcan sub-project
Presenter: Athénaïs Van Der Elst
Session: Poster Display
187P - Local and systemic anti-tumor response during tumor development in an immune privileged site: the case of uveal melanoma
Presenter: Francesca Lucibello
Session: Poster Display
188P - Expression of the co-stimulatory checkpoint protein OX40L (TNFSF4) in the melanoma micro-environment
Presenter: Raya Leibowitz-Amit
Session: Poster Display
189P - The impact of immune microenvironment subopopulations on soft tissue sarcomas
Presenter: Shokhrukhbek Khujaev
Session: Poster Display